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Background: Biotinidase deficiency (BD) is an inborn error of metabolism in which some genetic variants correlate with
the level of enzyme activity. Biotinidase activity, however, may be artifactually low due to enzyme lability, premature
birth, and jaundice; this hinders both phenotypic classification and the decision to implement therapy. This study sought
to characterize the clinical and genetic profile of a sample of Brazilian patients exhibiting reduced biotinidase activity.
Methods: This observational, multicenter study used a convenience sampling strategy, with sequencing of exons 2, 3,
and 4 of the BTD gene.
Results: The sample comprised 38 individuals with biochemical phenotypes defined a priori on the basis of biotinidase
activity in serum/plasma (2 with profound deficiency, 9 with partial deficiency, 15 heterozygous, 1 borderline between
partial deficiency and heterozygosity, 2 borderline between heterozygous and normal) or dried blood spot sample
(n = 9, all with unspecified deficiency). Most patients were from Southern Brazil (n = 29/38) and were identified by
neonatal screening (n = 33/38). Parental consanguinity was reported in two cases. The most commonly found genetic
variants were c.1330G > C (p.D444H), c.755A > G (p.D252G), and c.[511G > A;1330G > C] (p.[A171T;D444H]), with allele
frequencies of 50%, 9.4%, and 5.4% respectively. Three novel pathogenic variants were identified (c.119 T > C or p.L40P,
c.479G > A or p.C160Y, and c.664G > A or p.D222N). Twenty-nine patients had two pathogenic variants detected
(with cis/trans status ascertained in 26/29), six had only one variant, and three had no pathogenic variants detected.
Genotyping confirmed the original phenotypic classification based on enzyme activity in 16/26 cases. Three polymorphic
variants were identified in control individuals, of which two were nonpathogenic (c.1171C > T or p.P391S and c.1413
T > C or p.C471C, with a frequency of 1.5% and 5.5% respectively) and one pathogenic (c.1330G > C, frequency 4%).
Conclusions: Our findings suggest that partial BD is the most common form of BD in Brazil, and expand current
knowledge on the allelic heterogeneity of this condition.
Keywords: Low biotinidase, Genetic variants, Neonatal screening, BrazilBackground
Biotinidase deficiency (BD, EC 3.5.1.12) is an autosomal
recessive disease in which both the absorption of biotin
from dietary sources and its reuse/recycling are impaired.
This leads to a deficiency in biotin-dependent enzymes, such
as propionyl-CoA carboxylase (EC 6.4.1.3), β-methyl-
crotonyl-CoA carboxylase (EC 6.4.1.4), pyruvate carboxylase* Correspondence: idadschwartz@gmail.com
6Medical Genetics Service, Hospital de Clínicas de Porto Alegre (HCPA), Rua
Ramiro Barcelos, 2350, 90035-903 Porto Alegre, Brazil
Full list of author information is available at the end of the article
© 2014 Borsatto et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.(EC 6.4.1.1), and acetyl-CoA carboxylase (EC 6.4.1.2) [1,2].
Treatment, which consists of oral administration of free
biotin, is simple and effective when started early (e.g.,
before the onset of symptoms). If treatment is delayed,
there is a risk of irreversible damage (including hearing
and vision loss and mental retardation) and even death
[3-5]. The diagnosis of BD is confirmed by measurement
of biotinidase activity in plasma or serum. This test
enables classification of patients as having profound (or
total) BD (residual activity <10%) or partial BD (acti-
vity within 10-30% of average normal activity in serum).
Heterozygous individuals have enzyme activity levelsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Borsatto et al. BMC Medical Genetics 2014, 15:96 Page 2 of 7
http://www.biomedcentral.com/1471-2350/15/96between those of affected patients and those of homo-
zygous normal individuals [2]. This classification plays
an important role in instituting therapy, as patients with
profound BD should be treated and heterozygous indi-
viduals should not; there is no consensus on the need
for treatment of patients with partial BD [6].
However, enzyme testing is subject to interfering
factors that can produce artifactually low results, such as
the lability of biotinidase [7] and the direct correlation
between enzyme activity and gestational age and even
with postnatal age [8]. Furthermore, jaundiced neonates
may have reduced biotinidase activity [9]. Analysis of the
BTD gene is important, particularly to elucidate the
diagnosis when repeated enzyme testing yields discor-
dant results [10], in the assessment of premature infants
with reduced biotinidase activity, and in the assessment
of infants who have received blood transfusions [6].
Table 1 provides a review of what is known from the
literature about the association between the biochemical
phenotype and genotype in BD.
This study seeks to describe the clinical and genetic
profile of a sample of Brazilian patients presenting
reduced biotinidase activity.
Methods
This is a multicenter, observational, cross-sectional study
with a convenience sampling strategy. The study proto-
col was approved by the ethics committee of Hospital de
Clínicas de Porto Alegre (HCPA), and all patients and/or
their legal guardians provided written informed consent.
The study sample comprised 38 unrelated subjects
(21 male), aged 1 month to 18 years, who were recruited
from several regions of Brazil (29 from the South, 3 from
the Southeast, and 6 from the Northeast) during 2012–
2013 by contacting Brazilian medical geneticists through-
out the mailing list of the Brazilian Medical Genetics
Society. The criterion for inclusion was reduced bio-
tinidase activity (below the lower reference limit of
the testing laboratory). Clinical variables such as age,
biotinidase activity, and symptoms were obtained by a
review of medical records and by a data collection
form filled out by the referring physicians. For geneticTable 1 Molecular basis of biotinidase deficiency (BD)
BD
Profound BD Partial BD ≈ Hz
Profound deficiency allele Profound deficiency allele p.D444H
+ + +
Profound deficiency allele p.D444H p.D444H
Most variants in the BTD gene cause complete or almost complete loss of the biotin
c.98_104del7ins3, c.1612C > T (p.R538C), c.1368A > C (p.Q456H), c.[511G > A;1330G >
compound heterozygous form, results in profound BD. Individuals who are compou
deficiency allele are expected to have ~ 20-25% of the normal biotinidase activity. I
activity to individuals heterozygous (Hz) for profound deficiency alleles. Hz for p.D4
allele (normal activity, N). The p.D444H variant in cis with a mutation that causes pranalysis, blood was collected from patients and their
parents into EDTA-containing tubes. Overall, samples
from both parents were available for 27 patients, samples
from only one parent were available for 6 patients, and
5 patients had no parental samples available. Anonymous
samples from 100 healthy, adult controls from Southern
Brazil were tested for the c.1330G > C (p.D444H) variant
and for all novel variants first described in the present
study.
Biotinidase activity
Patients had undergone enzyme activity testing at
four different laboratories (A, B, C, and D), one of
which (laboratory A, n = 9/38 patients) only carries out
filter-paper testing, a technique that cannot quantitate the
degree of BD and expresses activity in units (U) (Neonatal
Biotinidase kit, PerkinElmer®, Wallac Oy, Turku, Finland).
In these cases, patients were diagnosed by the attending
staff as having BD after three consecutive abnormal tests
(below the 70U cutoff), and were thus not classified into
partial or profound BD. The activity presented in this
study is the average of the three tests (Table 2). The
remaining patients (n = 29/38) underwent quantitative
enzymatic testing (after abnormal neonatal screening or
clinical suspicion) at laboratories B, C, and D, in plasma
or serum, as described by Wolf et al. (1983) [2]. The nor-
mal reference range is 5.0–10 nmol/min/mL. The follow-
ing enzyme activity ranges were used for classification of
biochemical phenotype: <0.75, profound deficiency; 0.75–
2.25, partial deficiency; 2.26–4.9, heterozygosity. Values
within ± 0.1 of a cutoff point were classified as borderline.
When more than one measurement was available, the
highest level was used for classification (Table 2).
BTD gene analysis
Genomic DNA (gDNA) was extracted from blood col-
lected into EDTA-containing tubes using an Easy-DNA™
Kit (Invitrogen™, Carlsbad, CA, USA) in accordance with
manufacturer instructions. Exons 2, 3, and 4 and exon/
intron junctions of the BTD gene were amplified and
sequenced. Regions with detectable changes were assessed
in the patients’ parents (data not shown), to confirmUnaffected individuals
Hz ≈ N N
Profound deficiency allele p.D444H Wild-type allele
+ + +
Wild-type allele Wild-type allele Wild-type allele
idase enzyme activity; they are called profound deficiency alleles (e.g.,
C] (p.[A171T;D444H]). The presence of two such alleles, in homozygous or
nd heterozygotes for the c.1330G > C (p.D444H) variant and a profound
t is expected that individuals homozygous for the p.D444H variant have similar
44H variant show similar activity to individuals homozygous for the wild-type
ofound deficiency results in a profound deficiency allele [11-13].
Table 2 Biochemical and molecular profile of patients with reduced biotinidase activity (n = 38)










01 F c.643C > T (p.L215F) c.755A > G (p.D252G) Profound N/A 21.88 U NS
02c M c.755A > G (p.D252G) c.755A > G (p.D252G) Profound Profound 0.1; 0.4; 0.33;
0.44; 0.16; 0.32
S
03 F c.1612C > T (p.R538C) c.1612C > T (p.R538C) Profound Profound 0.12 S
04 M c.1330G > C (p.D444H) c.98_104del7ins3 Partial Partial 1.5 NS
05 F c.1330G > C (p.D444H) c.[470G > A;1330G > C]
(p.[R157H;D444H])
Partial Partial 1.8 NS
06 M c.1330G > C (p.D444H) c.[511G > A;1330G > C]
(p.[A171T;D444H])
Partial Partial 1.4 NS
07 F c.1330G > C (p.D444H) c.[511G > A;1330G > C]
(p.[A171T;D444H])
Partial Hz 2.5 NS
08 F c.1330G > C (p.D444H) c.[511G > A;1330G > C]
(p.[A171T;D444H])
Partial N/A 45.81 U NS
09 F c.1330G > C (p.D444H) c.594_596delCGT (p.V199del) Partial Partial 1.2; 1.9 NS
10 F c.1330G > C (p.D444H) c.[595G > A;1413 T > C]
(p.[V199M;C471C])
Partial Hz 2.8 NS
11 M c.1330G > C (p.D444H) c.755A > G (p.D252G) Partial Partial 1.7 NS
12 F c.1330G > C (p.D444H) c.755A > G (p.D252G) Partial Partial 1.2 NS
13 F c.1330G > C (p.D444H) c.755A > G (p.D252G) Partial Hz 2.4 NS
14 M c.1330G > C (p.D444H) c.755A > G (p.D252G) Partial N/A 51.37 U NS
15 M c.1330G > C (p.D444H) c.933delT Partial Partial 1.6 NS
16 F c.1330G > C (p.D444H)d c.100G > Ad Partial or Hz Partial 1.2; 2.04 NS
17 M c.1330G > C (p.D444H)d c.643C > T (p.L215F)d Partial or Hz Hz 2.4 NS
18 F c.1330G > C (p.D444H)d c.1629C > A (p.D543E)d Partial or Hz Hz 2.6 NS
19 M c.1413 T > C (p.C471C) c.[511G > A;1330G > C]
(p.[A171T;D444H])
Hz Hz 3.3 NS
20 M c.1595C > T (p.T532M) N Hz Hz 1.5; 2.9; 4.4 NS
21 M c.1330G > C (p.D444H) c.1330G > C (p.D444H) ≈ Hz Hz 0.7; 3.3 NS
22 M c.1330G > C (p.D444H) c.1330G > C (p.D444H) ≈ Hz Hz 3.7 NS
23 M c.1330G > C (p.D444H) c.1330G > C (p.D444H) ≈ Hz Hz 2.8; 2.7 NS
24 M c.1330G > C (p.D444H) c.1330G > C (p.D444H) ≈ Hz N/A 48.75 U NS
25 M c.1330G > C (p.D444H) c.1330G > C (p.D444H) ≈ Hz N/A 51.83 U NS
26 M c.1330G > C (p.D444H) c.1330G > C (p.D444H) ≈ Hz N/A 46.88 U NS
27c M c.1330G > C (p.D444H) c.1330G > C (p.D444H) ≈ Hz N/A 52.73 U NS
28 F c.1330G > C (p.D444H) c.1330G > C (p.D444H) ≈ Hz N/A 40.94 U NS
29 F c.1330G > C (p.D444H) c.1330G > C (p.D444H) ≈ Hz N/A 45.37 U NS
30 M c.1330G > C(p.D444H) N ≈ N Borderline (Hz/N) 4.9 NS
31 F c.1330G > C (p.D444H) N ≈ N Hz 3.1 NS
32 F c.1330G > C (p.D444H) N ≈ N Hz 3.8; 2.7 S
33 M c.1413 T > C (p.C471C) N N Borderline (Hz/N) 0.1; 2.6; 4.9 NS
34 F N N N Hz 4.1 S
35 M N N N Hz 3.7 S
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Table 2 Biochemical and molecular profile of patients with reduced biotinidase activity (n = 38) (Continued)
36 F c.1330G > C (p.D444H) c.119 T > C (p.L40P) Unknown Partial 1.7 NS
37 M c.1330G > C (p.D444H) c.479G > A (p.C160Y) Unknown Borderline (Partial/Hz) 0.2; 1.7; 2.2 NS
38 M c.664G > A (p.D222N) N Unknown Hz 3.5 NS
aThe cutoff for filter-paper tests performed at laboratory A is 70U. For quantitative testing in serum or plasma performed at laboratories B, C, D, the measurement
unit is nmol/min/mL and the reference range is 5.0-10. Unless otherwise specified, the unit of enzyme activity is nmol/min/mL.
bThe following enzyme activity ranges were used for phenotypic classification: <0.75, profound deficiency; 0.75-2.25, partial deficiency; 2.26-5.0, heterozygosity. If
more than one measurement was obtained, the highest value was considered. Values within ± 0.1 of a cutoff point were classified as borderline.
cPatients with consanguineous parents.
dWhether it is in cis or trans configuration with the other variant found remains undetermined.
Novel variants shown in bold type, and synonymous variants, in italics.
BD, biotinidase deficiency; F, female; M, male; NS, neonatal screening; S, symptoms; Hz, heterozygosity; N/A, not available; N, normal.
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reaction (PCR) was performed using previously described
primers [14] and the following annealing temperatures:
58°C for amplicons 2 and 3, 59°C for 4a, 60°C for 4b, and
62°C for 4c and 4d. PCR products were purified with
polyethylene glycol 8000 solution (PEG 8000 50%, NaCl
2.5 M) and sequenced using a BigDye® Terminator v3.1
Cycle Sequencing Kit and ABI 3500 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). Finally, the
resulting sequences were compared with the reference
sequence of the BTD gene (NG_008019.1).
For calculation of allele frequencies, the total number
of alleles was set at 74, as two patients were the children
of consanguineous parents.
A hundred control subjects were tested for the pre-
sence of variants c.119 T > C (p.L40P) and c.664G > A
(p.D222N) by restriction fragment length polymorphism
(RFLP) analysis – allele C of c.119 T > C introduces a site
for the restriction enzyme SmaI, whereas allele A of
c.664G >A removes a cleavage site for TaqI – and variants
c.479G >A (p.C160Y) and p.D444H by direct sequencing
of amplicons 4a and 4d respectively, which enabled identi-
fication of additional variants in these amplicons.
In silico analysis
All variants described in patients for the first time in this
study were evaluated for pathogenicity by in silico analysis
with PolyPhen-2 [15] and SIFT [16] softwares.
Genotype-phenotype association
Expected biochemical phenotype (e.g., profound DB,
partial DB or heterozygous state) was established accor-
ding to Table 1 only for genotypes composed of recurrent
pathogenic variants with a known cis/trans configuration,
and that are known to be associated with the phenotype.
Results
Clinical aspects
Of the 38 subjects included in the study (Table 2), only
two had profound BD. Nine patients had undergone filter-
paper screening alone, and thus had unspecified BD. Two
patients (5.3%, patients 02 and 27) had consanguineousparents. Only one subject (patient 03) had a family history
suggestive of BD recurrence – namely, a sister who died
at age 3 years with clinical manifestations consistent with
BD, but no confirmed diagnosis.
Thirty-three patients were identified by neonatal
screening, of whom 27 were on biotin (10 mg/day); none
had clinical manifestations suggestive of BD at the time
of inclusion. Six patients (patients 06, 12, 15, 19, 22, 33)
were preterm and had been born between 35 and
36 weeks of pregnancy. Neonatal jaundice was reported
for patients 20 and 33. Another five patients had been
diagnosed on the basis of clinical suspicion. In these
patients, the most common symptoms were visual distur-
bances, neurological manifestations, and skin lesions. The
age at onset of manifestations ranged from 1 day to
10 years, and the age at diagnosis from 40 days to 18 years.
All were receiving biotin supplementation (10–20 mg/day)
at the time of writing.
Genetic assessment
A total of 17 different alleles were found among the ana-
lyzed patients (Table 2): 13 recurrent pathogenic variants,
three novel variants (p.L40P, p.C160Y and p.D222N), and
one synonymous variant. No changes were found in exon
3. The most common variants were p.D444H, c.755A >G
(p.D252G) and p.[A171T;D444H], with allele frequencies
of 50%, 9.4%, and 5.4% respectively.
Twenty-nine patients had two pathogenic variants
detected (with cis/trans status ascertained in 26/29), six
had only one variant, and three had no pathogenic vari-
ants detected. Among patients in whom both classifica-
tion of biochemical phenotype and genotyping were
possible (n = 26/38), genotyping confirmed the original
classification in 16. Discordance between genotype and
biochemical phenotype was seen in seven cases: patients
07, 10 and 13 exhibited enzyme activity levels slightly
higher (suggestive of heterozygosity) than expected in
view of their genotype (suggestive of partial BD); and
patients 31, 32, 34 and 35 showed enzyme activity lower
(suggestive of heterozygosity) than expected in view of the
genotype (no variants found). In three subjects (patients
16, 17 and 18), the unclear cis/trans status prevented the
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36, 37 and 38, genotyping revealed novel variants, thus
precluding prediction of biochemical phenotype.
None of the three novel variants described herein were
found in controls and two out of them were predicted as
damaging by in silico analysis as well. The p.D222N vari-
ant had contradictory prediction between the two pro-
grams used (damaging by PolyPhen-2 and tolerated by
SIFT). The allele frequency of p.D444H in controls was
4% (six heterozygous and one homozygous individuals
for this variant were detected). Other variants found
in controls were c.460-7_8insT, c.1171C > T (p.P391S),
c.1284C > T (p.Y428Y) and c.1413 T > C (p.C471C)
and their frequencies were respectively 0.5%, 1.5%, 0.5%
and 5.5%.
Discussion
This study characterized the clinical and molecular pro-
file of Brazilian patients with reduced biotinidase activity
and, thus, at risk of BD. Before 2012, neonatal screening
for BD was unavailable through the public Unified
Health System in the majority of Brazilian states, and
was only provided by private laboratories located mainly
in the South and Southeast regions of the country,
which may have contributed to its underdiagnosis. Para-
doxically, studies based on neonatal screening suggest
that the overall frequency of BD (profound + partial BD)
in Brazil may be among the highest ever reported,
ranging from 1:6,843 to 1:62,500 newborns (NB) [17-20].
To the best of our knowledge, only one prior study
conducted DNA analysis of Brazilian patients with BD
(n = 21) [18].
Two studies conducted in the U.S., in which 92 pa-
tients with profound BD and 19 with partial BD were
assessed, showed that the most common BTD variants
in the study population were c.98_104del7ins3, c.1612C >T
(p.R538C), c.1368A >C (p.Q456H), p.[A171T;D444H] and
p.D444H, which, overall, accounted for approximately 60%
of abnormal alleles found in the sample [12,21]. Taking into
account this five-variant panel, p.[A171T;D444H] and p.
D444H account for approximately 55% of alleles detected
in the present study, with the occurrence of variants
c.98_104del7ins3 and p.R538C in only one patient each. In
our sample, we did not detect the variant p.Q456H, the
profound BD allele most commonly found among children
diagnosed by neonatal screening in the U.S. (allele fre-
quency = 28%) [21], nor did we find any changes in exon
3. Furthermore, p.D252G appeared to occur more com-
monly (allele frequency = 9.4%) in our sample than in the
U.S. population [21]. Our findings corroborate those of
Neto et al. (2004) [18], who analyzed the BTD gene
in 21 Brazilian patients with reduced biotinidase ac-
tivity detected by neonatal screening and also found
that p.D444H, c.98_104del7ins3, p.[A171T;D444H],and p.D252G were the most prevalent variants; the
authors also did not detect variant p.Q456H or changes in
exon 3 among their sample. Therefore, we suggest that
the profile of genetic variants found among Brazilian
patients with BD differs from that found in U.S. patients,
although these differences may be partly attributable to
the relatively small number of patients with profound BD
included in our sample (c.98_104del7ins3, p.R538C and
p.Q546H are classically associated with profound BD).
Since the p.D444H variant - usually classified as a par-
tial DB allele - was the most common variant found in
our study, our findings also suggest that partial BD is
the most common form of BD in Brazil. We found that
allele C of the variant c.1330G > C or p.D444H consti-
tuted 4% of alleles in healthy individuals, a frequency
close to that found in the U.S. population [22,23], where
the incidence of profound and partial BD has been
estimated at 1:80,000 NB and 1:31,000–1:40,000 NB
respectively [10], and in Western Hungary, where the inci-
dence of profound and partial BD is 1:97,000 NB and
1:23,000 NB respectively [24].
As previously reported, the association between BTD
genotype and biotinidase activity is not absolute [18,25].
In the Greek study conducted by Thodi et al. (2013)
[25], for instance, homozygosity for p.D444H was sug-
gested to be associated with partial BD, and not with a
45–50% reduction of biotinidase activity, as expected. In
the present study, among the seven cases of disagree-
ment between the observed and expected biochemical
phenotype, we highlight patient 10 because her genotype
p.D444H/c.595G > A (p.V199M) and p.V199M/p.V199M
have previously been reported in patients with residual
biotinidase activity levels of 32% and 11.5% respectively
[26], and it is possible that the p.V199M variant is not as
damaging as other profound BD alleles. Furthermore,
patient 31, from Northeast Brazil, and patients 32, 34
and 35, from the Southeast region, underwent testing at
a laboratory in the South region, so their biochemical
test results may have been artifactually low due to time
constraints or transportation of samples to the labora-
tory under inadequate conditions, as suggested by Neto
et al. (2004) [18]. However, we cannot rule out the
presence of changes in a region of the BTD gene not co-
vered by our analyses causing decreased enzyme activity.
In three patients, we were unable to define the cis/
trans status of variant p.D444H in relation to the other
variant found. On the basis of enzyme activity, trans sta-
tus is most probable for patient 16. For patient 17, who
presented with a biotinidase level suggestive of heterozy-
gosity (but very close to the upper limits of partial DB),
only gDNA from her mother, who also presented low
biotinidase activity in a dried spot blood sample (data not
shown), was available for analysis; as she was found to be
a carrier of both p.D444H and c.643C > T (p.L251F)
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were inherited on the maternal side (if they were in cis),
or have partial BD if p.D444H was inherited from the
father and only p.L215F from the mother (in this case,
the mother should also exhibit partial DB). Similarly,
both parents of patient 18, who is heterozygous for vari-
ants p.D444H and c.1629C > A (p.D543E), are hetero-
zygous for p.D444H, but the father is also a carrier of
p.D543E; therefore, the patient can be heterozygous if
p.D444H and p.D543 are in cis in the paternal allele,
or can have partial DB if they are in trans (in which
case the father should also exhibit partial DB). A new
enzyme activity test in the child and testing of parents
(or even analysis of grandparent DNA) could help
characterize BD in this case.
Although the enzyme activity of symptomatic patients
32, 34 and 35 was not consistent with profound or par-
tial BD, biotin treatment was started after other genetic
conditions had been ruled out, as the patients’ clinical
manifestations are consistent with BD and biotin has a
good safety profile. Unfortunately, we are not aware
whether there was any improvement with treatment.
These patients may represent cases of delayed-onset BD,
but the absence of variants in exons 2–4 of the BTD
gene suggest they do not have BD. Patient 33 is also very
interesting, since his biotinidase activity levels were very
low on neonatal screening, and gradually approached
the normal range thereafter, as would be expected to his
genotype. We believe the wide variation in biotinidase
levels presented by this patient is mainly explained by
premature birth and neonatal jaundice. However, as the
first test was performed when he was only 5 days old
and the last at age 1 year, some of this variation could
also be due to increasing age.
On the basis of the allele frequency of novel variants
p.L40P and p.C160Y in controls and of the in silico pre-
diction of pathogenicity, and taking observed enzyme
activity into account, these alleles were considered
probably damaging, and patients 36 and 37, who are
compound heterozygous for the p.D444H variant, prob-
ably have partial BD. Variant p.L40P does not affect the
peptide portion that constitutes the mature protein, but
affects the signal peptide, which may impair targeting of
the enzyme to secretory vesicles, thus resulting in
reduced enzyme activity in plasma. Alleles associated
with profound BD which affect this region have been de-
scribed elsewhere [27,28]. The effect of variant p.D222N
on biotinidase function could not be established clearly
from bioinformatics, as we used two different software
programs which presented contradictory conclusions
regarding this variant. However, the absence of this
variant in controls suggests it is probably damaging.
Regarding the other two nonpathogenic polymorphic
variants found in controls, c.1171C > T or p.P391S(rs35034250) and c.1413 T > C or p.C471C (rs3817641),
both were found at frequencies similar to those reported
in populations of USA and African origin respectively
(available at: http://www.ncbi.nlm.nih.gov/snp/).
Conclusion
Genotyping of Brazilian patients with reduced biotini-
dase activity broadened current knowledge on the allelic
heterogeneity of BD. Furthermore, the high frequency of
the p.D444H variant in patients and controls suggest
that the incidence of partial BD in Brazil may be higher
than worldwide estimates. When enzyme activity approa-
ches the border between partial BD and heterozygosity,
sequencing of the BTD gene (starting with analysis of
exons 2 and 4) appears to be the most appropriate
technique to elucidate the diagnosis in this population.
We suggest that parental DNA analysis be carried out
whenever the p.D444H variant and another variant are
detected in a BD patient.
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